Clinical Trial Update: A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). [Phase 3]

View source ↗

Summary

A phase 3 trial assessing safety, tolerability, and immunogenicity of 9-valent HPV vaccine (V503) in Japanese girls aged 9-15; trial completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Genital Warts
• Papillomavirus Infections

Drugs mentioned

• 9-valent human papillomavirus vaccine (V503) (9-valent human papillomavirus vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Papillomavirus Infections | Phase 3 | Status: COMPLETED | Results posted: 2014-12-22